Therapies that increase BAs (or mimetics) in the distal bowel as a means of increasing endogenous GLP-1 concentrations have been suggested as novel treatments of T2DM and obesity [56]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.